Orthocell’s Collagen Nerve Wrap, Remplir, Now Available to Australian Urologists for Prostate Surgery Recovery
Australian urologists can now access Remplir to support nerve protection and recovery during robotic prostate cancer surgeries.
Orthocell has made its collagen nerve wrap, Remplir, available to Australian urologists for use in nerve-sparing robotic-assisted radical prostatectomies (RARP). Remplir has now been used in roughly 40 prostate cancer surgeries to support recovery of erectile function and urinary continence, complications often resulting from nerve injury during these procedures.
Remplir is a collagen nerve wrap designed to aid in the repair of peripheral nerve injuries. The company mentions it provides compression-free protection to nerves, creating an environment conducive to nerve healing. Manufactured with Orthocell’s proprietary SMRT™ process, Remplir may preserve collagen structure for better tissue integration. In peripheral nerve repair, the device enables tensionless nerve reconstruction, which can lower the risk of further nerve damage and reduce the need for sutures, potentially shortening surgery times.
After radical prostatectomy, up to 80% of men experience erectile dysfunction and up to 35% experience urinary incontinence, largely due to damage to the neurovascular bundle (NVB)—a group of nerves around the prostate. Even with nerve-sparing techniques and robotic-assisted procedures, these complications remain common. Remplir’s new intention is to protect the NVB during surgery and promote restoration of nerve function, similar to its established use in repairing peripheral nerves in the arms and legs.
Orthocell is working with urologists to collect clinical data from these initial cases and plans to release outcomes when available. The company also reports plans to invest in further clinical studies and medical education to encourage broader adoption of Remplir for this application. Initial rollout of Remplir in the United States is underway, with Orthocell collaborating with distributors, hospitals, and surgeons as the first US surgical cases begin.
Stay Ahead in Regenerative Medicine
Thanks! Your signup has been saved.
Orthocell CEO and MD, Paul Anderson, said:
“Surgeons across multiple specialties—including orthopaedics, plastic and reconstructive surgery, and now urology—are increasingly adopting Remplir to simplify procedures, minimise scarring, and improve functional recovery.
“This represents a significant step forward in Remplir’s organic expansion into broader peripheral nerve repair applications and has the potential to substantially increase the device’s global total addressable market.”
Want to keep up on regenerative medicine? Get the weekly newsletter here.
Similar stories
Made Scientific Selected to Manufacture Columbia University’s NOVAKnee, a 3D Printed Knee Replacement Made of Stem Cells and Scaffolds
BioStem Technologies Receives 5 Patents for Placental Allografts
Kangstem Publishes Promising Phase 1 Results for Cord-Blood Derived Stem Cell Therapy in Knee Osteoarthritis, Post-MRI Data Suggest Potential Cartilage Regeneration
Royal Biologics and Jellagen Bringing Jellyfish-Derived Collagen Type Zero to the US Regenerative Medicine MarketEditor’s Picks
Century Therapeutics Reports Sustained Glucose Control With iPSC-Derived Islets in Diabetic Mice, IND Soon
Umbilical Cord Mesenchymal Stem Cell Injections Lower Pain Scores More Than Hyaluronate in 50-Patient Severe Knee Osteoarthritis Trial
Stempeutics Nabs US Patent for Osteoarthritis Treatment Combining Bone Marrow Stem Cells and Hyaluronic Acid
Inside Cellular Intelligence: The Zuck-Backed AI Company That Acquired Novo’s Parkinson’s Cell Therapy
